Humanigen Inc

Humanigen Inc finds support for its strategy in treating graft-versus-host disease in medical journal article

The study preventing GM-CSF signaling reduces acute GvHD, which is what Humanigen's drug, lenzilumab is designed to do

Person in scrubs reading tablet
The company is currently planning a Phase 2 trial in the UK in patients at high risk of acute GvHD

Humanigen Inc (OTCMKTS:HGEN) told investors Tuesday that a recent study published in the medical journal Blood Advances supports its strategy in the development of a treatment for severe graft-versus-host disease (GvHD). 

The study found that GM-CSF, a protein involved in the creation of white blood cells, is necessary to initiate a cascade that drives lethal GvHD. If GM-CSF isn’t able to give off signals, however, the study showed a significant reduction in the disease.

That’s where Humanigen’s drug lenzilumab, an anti-GM-CSF immunotherapy, comes in.

READ: Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich

The California-based company is currently planning a Phase 2 trial in the UK for patients at high risk of acute GvHD. 

In July, Humanigen received an exclusive worldwide license from the University of Zurich for technologies to prevent and treat GvHD through GM-CSF neutralization.

Blood Advances is the official journal of the American Society of Hematology. The article, published Tuesday, is entitled “Donor T-cell derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract.”

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Humanigen Inc

Price: 0.7 USD

Market Cap: $78.94 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen Inc named herein, including the promotion by the Company of Humanigen Inc in any Content on the Site, the Company receives from said...



Humanigen inks licensing agreement with the University of Zurich to...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based company has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers. Durrant says Humanigen has received an exclusive licensing...

on 22/7/19

2 min read